1-year data set Spark/Pfizer on track with hemophilia B gene therapy … – FierceBiotech
FierceBiotech |
1-year data set Spark/Pfizer on track with hemophilia B gene therapy …
FierceBiotech Patients with hemophilia B have seen their symptoms controlled for up to a year with a single dose of a gene therapy developed by Spark Therapeutics, almost entirely eliminating the need for treatment with clotting factors. Over the course of the … Improvements to Gene Therapy Clinical Trial Design Benefit Hemophilia Patients Inflammatory factors linked to inhibition of factor VIII gene therapy in hemophilia A Spark gene therapy nearly eliminates bleeding episodes in hemophilia B patients |
